Brenton Karl Ahrens - Net Worth and Insider Trading
Brenton Karl Ahrens Net Worth
The estimated net worth of Brenton Karl Ahrens is at least $570 dollars as of 2024-11-11. Brenton Karl Ahrens is the Director of Iterum Therapeutics PLC and owns about 410 shares of Iterum Therapeutics PLC (ITRM) stock worth over $570. Details can be seen in Brenton Karl Ahrens's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Brenton Karl Ahrens has not made any transactions after 2022-09-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Brenton Karl Ahrens
Brenton Karl Ahrens Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Brenton Karl Ahrens owns 2 companies in total, including Iterum Therapeutics PLC (ITRM) , and DexCom Inc (DXCM) .
Click here to see the complete history of Brenton Karl Ahrens’s form 4 insider trades.
Insider Ownership Summary of Brenton Karl Ahrens
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
ITRM | Iterum Therapeutics PLC | 2022-09-20 | director |
DXCM | DexCom Inc | 2005-04-13 | director |
Brenton Karl Ahrens Latest Holdings Summary
Brenton Karl Ahrens currently owns a total of 1 stock. Brenton Karl Ahrens owns 410 shares of Iterum Therapeutics PLC (ITRM) as of September 20, 2022, with a value of $570.
Latest Holdings of Brenton Karl Ahrens
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
ITRM | Iterum Therapeutics PLC | 2022-09-20 | 410 | 1.39 | 570 |
Holding Weightings of Brenton Karl Ahrens
Brenton Karl Ahrens Form 4 Trading Tracker
According to the SEC Form 4 filings, Brenton Karl Ahrens has made a total of 3 transactions in Iterum Therapeutics PLC (ITRM) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Iterum Therapeutics PLC is the sale of 37,246 shares on September 20, 2022, which brought Brenton Karl Ahrens around $67,788.
Insider Trading History of Brenton Karl Ahrens
- 1
Brenton Karl Ahrens Trading Performance
GuruFocus tracks the stock performance after each of Brenton Karl Ahrens's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Brenton Karl Ahrens is -16.21%. GuruFocus also compares Brenton Karl Ahrens's trading performance to market benchmark return within the same time period. The performance of stocks bought by Brenton Karl Ahrens within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Brenton Karl Ahrens's insider trading performs compared to the benchmark.
Performance of Brenton Karl Ahrens
Brenton Karl Ahrens Ownership Network
Ownership Network List of Brenton Karl Ahrens
Ownership Network Relation of Brenton Karl Ahrens
Brenton Karl Ahrens Owned Company Details
What does Iterum Therapeutics PLC do?
Who are the key executives at Iterum Therapeutics PLC?
Brenton Karl Ahrens is the director of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .
Iterum Therapeutics PLC (ITRM) Insider Trades Summary
Over the past 18 months, Brenton Karl Ahrens made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , and a net purchase of 10,000 shares made by Fishman Corey N. .
In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 65,000 shares.
Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Iterum Therapeutics PLC Insider Transactions
Brenton Karl Ahrens Mailing Address
Above is the net worth, insider trading, and ownership report for Brenton Karl Ahrens. You might contact Brenton Karl Ahrens via mailing address: 2765 Sand Hill Road, Menlo Park Ca 94025.